Alyeska Investment Group L.P. Cuts Stock Holdings in Evolus, Inc. $EOLS

Key Points

• Alyeska Investment Group L.P. reduced its stake in Evolus, Inc. by 30.8%, now owning 225,000 shares worth approximately $2.7 million.
• Insider trading activity included CMO Tomoko Yamagishi-Dressler selling 5,722 shares, while Director Brady Stewart purchased 30,000 shares, indicating a mixed sentiment among company insiders.
• Analysts have downgraded Evolus’ price targets, with BTIG Research and HC Wainwright lowering their targets to $18.00 and $20.00, respectively, while maintaining a "buy" rating.

Alyeska Investment Group L.P. cut its stake in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 30.8% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 225,000 shares of the company's stock after selling 100,000 shares during the quarter. Alyeska Investment Group L.P. owned 0.35% of Evolus worth $2,707,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. AlphaQuest LLC purchased a new position in shares of Evolus during the 1st quarter valued at about $39,000. State of Wyoming lifted its holdings in Evolus by 988.1% during the first quarter. State of Wyoming now owns 3,754 shares of the company's stock valued at $45,000 after purchasing an additional 3,409 shares in the last quarter. IFP Advisors Inc lifted its holdings in Evolus by 99.0% during the first quarter. IFP Advisors Inc now owns 9,427 shares of the company's stock valued at $113,000 after purchasing an additional 4,691 shares in the last quarter. Rafferty Asset Management LLC bought a new position in shares of Evolus in the fourth quarter worth approximately $115,000. Finally, Man Group plc bought a new stake in shares of Evolus during the 4th quarter valued at $121,000. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Evolus Price Performance

EOLS traded up $0.16 on Thursday, reaching $7.51. 746,924 shares of the company's stock were exchanged, compared to its average volume of 899,229. The stock has a market cap of $485.75 million, a PE ratio of -7.66 and a beta of 1.07. The stock's fifty day moving average price is $8.12 and its 200-day moving average price is $10.00. Evolus, Inc. has a twelve month low of $5.71 and a twelve month high of $17.82. The company has a debt-to-equity ratio of 22.00, a current ratio of 2.27 and a quick ratio of 1.86.

Insider Buying and Selling

In other Evolus news, Director Brady Stewart purchased 30,000 shares of Evolus stock in a transaction dated Friday, August 15th. The shares were acquired at an average price of $6.82 per share, with a total value of $204,600.00. Following the completion of the transaction, the director owned 88,629 shares of the company's stock, valued at $604,449.78. This trade represents a 51.17% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider David Moatazedi sold 16,582 shares of Evolus stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $9.89, for a total transaction of $163,995.98. Following the completion of the transaction, the insider owned 364,927 shares of the company's stock, valued at $3,609,128.03. This trade represents a 4.35% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 133,627 shares of company stock valued at $1,325,764. 5.90% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Wall Street Zen lowered shares of Evolus from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. HC Wainwright decreased their target price on shares of Evolus from $27.00 to $20.00 and set a "buy" rating on the stock in a research report on Wednesday, August 6th. BTIG Research reaffirmed a "buy" rating and issued a $18.00 price target on shares of Evolus in a report on Monday. Finally, Needham & Company LLC reissued a "hold" rating and set a $22.00 price objective on shares of Evolus in a research note on Wednesday, August 6th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, Evolus has a consensus rating of "Moderate Buy" and an average target price of $21.25.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.